8-K: Viridian Therapeutics Appoints Seth Harmon as Chief Financial Officer

Viridian Therapeutics announces the appointment of Seth Harmon as its new Chief Financial Officer, effective January 1, 2025.

Summary

• Viridian Therapeutics has appointed Seth Harmon as Chief Financial Officer, effective January 1, 2025.
• Harmon previously served as Senior Vice President of Finance and Accounting since May 2023 and Principal Financial Officer and Principal Accounting Officer since September 2023.
• Prior to joining Viridian, Harmon was CFO and VP of Finance and Administration for BioNTech SE's U.S. subsidiary and VP of Finance and Accounting at Neon Therapeutics.
• His base salary has been increased to $480,000, and his target discretionary bonus remains at 40% of his base salary.
• Harmon will receive a stock option award with a grant date value of $1,662,000 and a restricted stock unit award with a grant date value of $554,000.
• An updated employment agreement will be filed with the company's Annual Report on Form 10-K for the year ended December 31, 2024.

Sentiment

Score: 7

Explanation: The announcement is generally positive, indicating stability and growth with the appointment of a qualified CFO. The compensation package is competitive and aligns with industry standards.

Positives

• The appointment of an experienced financial executive like Seth Harmon as CFO is a positive step for Viridian Therapeutics.
• Harmon's previous roles at BioNTech and Neon Therapeutics suggest he has relevant experience in the biotechnology industry.
• The equity awards granted to Harmon align his interests with those of the company's shareholders.

Future Outlook

The company will file an updated employment agreement with the Annual Report on Form 10-K for the year ended December 31, 2024.

Industry Context

The appointment of a CFO is a standard corporate governance practice, especially for publicly traded companies like Viridian Therapeutics in the biotechnology sector. Harmon's experience at BioNTech, particularly, is relevant given the increasing focus on innovative therapies and global operations in the biotech industry.

Comparison to Industry Standards

• CFO compensation packages in the biotech industry typically include a base salary, bonus potential, and equity awards.
• Base salaries for CFOs in similar-sized biotech companies often range from $350,000 to $600,000, making Harmon's $480,000 salary within the expected range.
• Equity awards are a significant component of CFO compensation, aligning their interests with shareholders; the combined value of Harmon's stock options and restricted stock units is substantial.
• Comparing Viridian to companies like Alnylam Pharmaceuticals or Sarepta Therapeutics, which are also focused on innovative therapies, provides a benchmark for executive compensation and strategic financial leadership.

Management Changes

Stakeholder Impact

• Shareholders may view the appointment positively, as it brings financial expertise to the company.
• Employees may see it as a sign of stability and growth.
• The appointment does not appear to have a direct impact on customers, suppliers, or creditors.

Next Steps

• The updated employment agreement between Mr. Harmon and the Company will be filed as an exhibit to the Company's Annual Report on Form 10-K for the year ended December 31, 2024.

Key Dates